亿帆医药(002019) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 reached ¥1,226,121,751.43, an increase of 24.32% compared to the same period last year[3] - Net profit attributable to shareholders was ¥113,153,515.29, representing a significant growth of 196.33% year-over-year[3] - The net profit excluding non-recurring items increased by 278.78% to ¥72,561,252.06[3] - Year-to-date revenue reached ¥3,858,211,534.78, up 31.67% from the previous year, driven by new and existing pharmaceutical products[4] - The company reported a basic earnings per share of ¥0.09, a 200.00% increase compared to the same period last year[3] - Operating profit for the current period was ¥383,633,544.49, compared to ¥125,123,271.54 in the previous period, reflecting a significant improvement[25] - Net profit attributable to shareholders of the parent company was ¥366,380,130.89, up from ¥146,845,650.22 in the previous period, indicating a growth of 149.5%[25] - The company reported a total comprehensive income of ¥296,934,756.14 for the current period, compared to ¥126,602,162.46 in the previous period[25] - The basic earnings per share increased to ¥0.30 from ¥0.12, indicating improved profitability[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,369,758,873.71, reflecting a 7.57% increase from the end of the previous year[4] - The company’s total assets as of September 30, 2024, amounted to 12,369,758,873.71 RMB, an increase from 11,499,585,782.14 RMB at the beginning of the period[23] - The company’s total liabilities as of September 30, 2024, were 3,950,405,928.04 RMB, compared to 3,244,679,252.50 RMB at the beginning of the period[23] - The company’s long-term equity investments decreased to 678,485,929.75 RMB from 702,036,940.60 RMB at the beginning of the period[22] - The company’s intangible assets increased to 1,795,272,887.62 RMB from 1,682,766,736.54 RMB at the beginning of the period[22] Cash Flow - Cash flow from operating activities for the year-to-date increased by 37.27% to ¥353,409,624.07[5] - Cash flow from operating activities generated a net amount of ¥353,409,624.07, an increase from ¥257,455,574.19 in the previous period[27] - The company recorded a cash inflow from investment activities of ¥482,394,728.40, down from ¥1,165,805,574.10 in the previous period[27] - The net cash flow from financing activities was negative at -¥368,697,671.99, contrasting with a positive inflow of ¥5,452,331.50 in the previous period[27] - Cash and cash equivalents at the end of the period reached $899,762,155.39, up from $682,980,477.18 year-over-year[28] - The company reported a cash increase of $327,016,274.20, contrasting with a decrease of $28,645,149.23 in the same quarter last year[28] - The company’s cash outflow for debt repayment was $1,173,759,041.66, down from $1,609,834,754.59 in the previous period[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 40,435[11] - The largest shareholder, Cheng Xianfeng, holds 40.82% of the shares, totaling 496,526,307 shares[11] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 2.72% of the shares, totaling 33,102,753 shares[11] - The company has not identified any related party relationships among shareholders other than those mentioned[12] - The report indicates that Zheng Zhen holds 14,942,418 shares through a credit account, while Huang Xiaomin holds 11,061,800 shares through a credit account[12] Dividends and Distributions - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 121,639,008.50 RMB, which accounts for 48.04% of the net profit attributable to shareholders for the first half of 2024[17] - The company paid $192,954,021.33 in dividends, interest, or profit distributions, compared to $63,076,408.75 in the previous year[28] Research and Development - Research and development expenses increased to ¥182,438,180.13 from ¥175,652,095.07, showing a commitment to innovation[24] Marketing and Sales - Sales expenses rose to ¥962,031,504.27 from ¥780,288,516.31, reflecting increased marketing efforts[24] Regulatory and Compliance - The company’s subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the drug registration certificate for Mesobam Injection on August 5, 2024, from the National Medical Products Administration[16] - The company’s subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the drug registration certificate for Famotidine Injection in mid-September 2024[16] Guarantees and Contracts - The company provided guarantees for its wholly-owned subsidiary Hefei Yifan Biological Pharmaceutical Co., Ltd. on July 1, 2024, with a guarantee contract signed with China Industrial Bank[14] - The company adjusted unused guarantee limits of 20 million RMB to Hefei Yifan Biological Pharmaceutical Co., Ltd. on July 15, 2024[15] - The company also adjusted unused guarantee limits of 230 million RMB to Hefei Yifan Biological Pharmaceutical Co., Ltd. on August 19, 2024[15] Accounting and Auditing - The company has not yet audited the third-quarter report[28] - The company began implementing new accounting standards from the beginning of 2024[28]